secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0000879169-26-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q4 total revenue $1.51B (+28% YoY); FY 2025 net product revenue beat guidance
--------------------------------------------------------------------------------

- Q4 total revenue $1.51B (+28% YoY); net product revenue $1.22B (+20%). FY 2025 net product revenue $4.35B, above $4.23-4.32B guidance.
- GAAP diluted EPS Q4 $1.46, FY $6.41; non-GAAP diluted EPS Q4 $1.80, FY $6.80.
- 2026 total net product revenue guidance $4.77-4.94B, including Jakafi $3.22-3.27B and Opzelura $750-790M.
- Pipeline: positive frontMIND Phase 3 for tafasitamab in DLBCL; Jakafi XR filing submitted, decision mid-2026; INCA033989 registrational plans; ruxolitinib cream PN paused.
- Cash $3.6B; entered option agreement with Prelude Therapeutics for JAK2V617F inhibitor program ($100M option exercise).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/0000879169-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-20260210.htm
  HTML page:      https://secwatch.observer/filing/0000879169-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer